Psilocybin
The active compound in "magic mushrooms," and the psychedelic closest to FDA approval. Researchers are studying it for depression, the distress that can come with a terminal diagnosis, and addiction.
Last reviewed: November 2, 2026
The basics
Psilocybin is turned into psilocin in the body, which acts mainly on the brain's serotonin 2A receptors. In clinical trials it is given as one or two doses, with trained support before, during and after the session. That model, a few guided sessions instead of a daily pill, is what makes it different from today's antidepressants.
| Where | Status |
|---|---|
| United States, federal | Schedule I. A final FDA filing for the first psilocybin treatment is expected by the end of 2026. |
| Oregon | Licensed service centers, created by Measure 109 (2020), open since 2023. |
| Colorado | Licensed healing centers under the Natural Medicine Health Act (2022). Psilocybin is the only medicine offered in centers so far. |
| New Mexico | Medical Psilocybin Act signed April 2025. The state is aiming to open its clinician-led program by December 2026. |
Foundational studies
What's happening now
Capped at five. Oldest rotates to the archive at each review.
From the show
Dennis McKenna on Psychedelics as Medicine
Dr. DREAM sits down with legendary ethnopharmacologist Dennis McKenna for a wide-ranging conversation on DMT, ayahuasca, psilocybin, indigenous wisdom, consciousness, and the evolving future of psychedelic medicine.
Watch on YouTube →The Reality of Psilocybin Therapy - Is It For You?
Dr. DREAM speaks with Dave Naftalin. Dave is a trailblazer in the emerging field of psilocybin therapy, renowned for being the first licensed psilocybin facilitator in the nation.
Watch on YouTube →Go deeper
This page is for education only and is not medical advice. Psilocybin remains a Schedule I substance under federal law. Talk with a qualified professional before making any health decision.